source
- BlossomHill Therapeutics targets $112 million IPO to fund EGFR lung-cancer drug BH-30643BlossomHill Therapeutics, a San Diego oncology biotech, announced plans for an initial public offering to raise about $112 million. The company intends to sell 7.8 million shares at $15-$17 each,…
- China's biotech surge highlights work-life tension for industry leadersChina's biotechnology sector is accelerating, prompting discussions about the demanding work culture among its leaders. Shefali Agarwal, the US‑based chief executive of Sironax, said she works lon…